# Relmada Therapeutics, Inc.: Form D filings

Relmada Therapeutics, Inc., a biotechnology company in New York, NY, filed 4 Form D notices with the SEC between 2012 and 2014. The latest, on May 22, 2014, reports $15.1 million sold of a $15.1 million offering to 225 investors.

Find out what Relmada Therapeutics, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.

- [Watch for new raises](https://specstream.ai/workspace/ask?q=Tell%20me%20when%20Relmada%20Therapeutics%2C%20Inc.%20files%20a%20new%20Form%20D%20or%20reports%20more%20money%20sold%2C%20with%20the%20filing&src=data-formd&kind=alert&entity=Relmada%20Therapeutics%2C%20Inc.&page=%2Fdata%2Fform-d%2Fcompany%2Frelmada-therapeutics-inc-1554535)
- [Get founders and investors](https://specstream.ai/workspace/ask?q=For%20Relmada%20Therapeutics%2C%20Inc.%2C%20find%20what%20the%20company%20does%2C%20its%20website%2C%20the%20founders%20and%20executives%20with%20their%20LinkedIn%20and%20work%20email%2C%20its%20investors%20and%20every%20funding%20round%20with%20the%20amounts%2C%20its%20headcount%20and%20any%20reported%20valuation&src=data-formd&kind=record&entity=Relmada%20Therapeutics%2C%20Inc.&page=%2Fdata%2Fform-d%2Fcompany%2Frelmada-therapeutics-inc-1554535)

## The full lists

This record is a row of these lists. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email.

- [Form D filings in New York](https://specstream.ai/data/form-d/state/new-york): 4,357 rows, by operating companies, filed since November 1, 2024, $123.57, or the new rows each week for $19 a month. Buy: https://specstream.ai/data/form-d/state/new-york
- [Form D filings in Biotechnology](https://specstream.ai/data/form-d/industry/biotechnology): 1,568 rows, by operating companies, filed since November 1, 2024, $78.40, or the new rows each week for $19 a month. Buy: https://specstream.ai/data/form-d/industry/biotechnology

SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.

## Company details from the filing

- Address: 546 FIFTH AVENUE, 14TH FLOOR, New York, NY, 10036
- Phone: (212) 702-7163
- Industry: Biotechnology
- Entity type: Corporation
- Incorporated in: Delaware
- Revenue range: No Revenues
- Exemptions claimed: Rule 506(b)
- SEC identifier (CIK): 1554535

## Form D filings

| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
| --- | --- | --- | --- | --- | --- | --- | --- |
| May 22, 2014 | New notice | $15,051,110 | $15,051,110 | $0 | 225 | May 12, 2014 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1554535/000121390014003729/0001213900-14-003729-index.htm) |
| Jun 7, 2013 | New notice | $750,000 | $180,000 | $570,000 | 6 | Dec 6, 2012 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1554535/000121390013003014/0001213900-13-003014-index.htm) |
| Jun 6, 2013 | Amendment | $8,000,000 | $4,955,500 | $3,044,500 | 98 | Jul 10, 2012 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1554535/000121390013003005/0001213900-13-003005-index.htm) |
| Jul 23, 2012 | New notice | $6,000,000 | $3,008,000 | $2,992,000 | 61 | Jul 10, 2012 | [sec.gov](https://www.sec.gov/Archives/edgar/data/1554535/000155453512000002/0001554535-12-000002-index.htm) |

## Executive officers and directors named in the filing

| Name | Role | Note in the filing |
| --- | --- | --- |
| Eliseo O. Salinas | Executive Officer |  |
| Douglas O. Beck | Executive Officer |  |
| Sandesh O. Seth | Director |  |
| Shreeram O. Agharkar | Director |  |
| Nabil M. Yazgi | Director |  |
| Sergio Traversa | Executive Officer, Director |  |

## Other biotechnology companies in New York that filed recently

- [Swep Bio, Inc.](https://specstream.ai/data/form-d/company/swep-bio-inc-2159106) $2.5 million · Oct 29, 2026
- [Hypercell Technologies Inc.](https://specstream.ai/data/form-d/company/hypercell-technologies-inc-1882357) $3 million · Oct 14, 2026
- [CAD Therapeutics, Inc.](https://specstream.ai/data/form-d/company/cad-therapeutics-inc-2157566) $4 million · Oct 2, 2026
- [Vicora, Inc.](https://specstream.ai/data/form-d/company/vicora-inc-2091847) $2.3 million · Sep 18, 2026
- [GevRx Nutraceuticals, Inc.](https://specstream.ai/data/form-d/company/gevrx-nutraceuticals-inc-2156105) $300,000 · Sep 18, 2026
- [Episteme Prognostics, Inc.](https://specstream.ai/data/form-d/company/episteme-prognostics-inc-1902402) $5.1 million · Sep 4, 2026

[Every Form D from the week of May 19, 2014](https://specstream.ai/data/form-d/week/2014-05-19) · [All recent filings in New York](https://specstream.ai/data/form-d/state/new-york) · [All recent Biotechnology filings](https://specstream.ai/data/form-d/industry/biotechnology)

Read from SEC EDGAR. Amount sold is what Relmada Therapeutics, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under [CC BY 4.0](https://creativecommons.org/licenses/by/4.0/).